Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model (Q39305333)

10 September 2017

Nano-encapsulation of plitidepsin: in vivo pharmacokinetics, biodistribution, and efficacy in a renal xenograft tumor model (English)

1 reference

10 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Emmanuel Ibarboure

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sébastien Lecommandoux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Julie Thevenot

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Elisabeth Garanger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Pilar Calvo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Pablo Aviles

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Maria Jose Guillen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

28 November 2013

1 reference

10 September 2017

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

983-991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24287622%20AND%20SRC:MED&resulttype=core&format=json

Nanoparticle therapeutics: an emerging treatment modality for cancer

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Nanoparticle technologies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Smart polymersomes for therapy and diagnosis: fast progress toward multifunctional biomimetic nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

JNK activation is critical for Aplidin-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Biocompatible and biodegradable poly(trimethylene carbonate)-b-poly(L-glutamic acid) polymersomes: size control and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

A new potential nano-oncological therapy based on polyamino acid nanocapsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Biodegradable long-circulating polymeric nanospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1220-3

Hypersensitivity reactions from taxol

21 January 2018

1 reference

12 December 2020

Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system

1 reference

12 December 2020

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration

1 reference

12 December 2020

Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer

1 reference

12 December 2020

Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta

1 reference

12 December 2020

Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation

1 reference

12 December 2020